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As a heterogeneous group of blood cancers, acute myeloid leukemia (AML) is subdivided into risk 
groups according to chromosomal translocations and gene mutations. Precisely which cell originally 
acquires these molecular alterations is unclear, but could explain why some patients with low-risk 
mutations respond poorly to treatment or why some patients with high-risk mutations do well. To 
address this question, the laboratory of Dr. Roland Walter in the Clinical Research Division 
developed new methods to culture the small numbers of immature cells from AML patients. Their 
study, published in the journal Leukemia, confirmed that the cell of mutation origin varies between 
individual AML patients and influences clinical outcomes. 
Several decades ago, researchers at the University of Washington and the Fred Hutchinson Cancer 
Research Center suggested the cell of mutation origin varies between individual AML patients 
(Fialkow et al., 1987). The researchers examined X chromosome inactivation patterns across 
different types of mature blood cells in female AML patients. In healthy individuals, X chromosome 
inactivation is polyclonal among red and white blood cells. In contrast, in some AML patients, both 
red and white blood cells had clonal X inactivation, suggesting that leukemic mutations originated in 
a hematopoietic stem cell that gives rise to both cell types. Other AML patients presented with clonal 
expansion only in myeloid cells, a subset of white blood cells, suggesting the genetic change driving 
leukemogenesis occurred in a more committed precursor cell.  
In the current study, Walter and colleagues developed methods to specifically isolate and study the 
rare immature stem/progenitor cells from AML patient specimens. The researchers mimicked 
conditions found in the bone marrow niche where stem cells reside, including low oxygen conditions 
and co-culture with engineered endothelial cells (Butler JM, et al., 2010). The AML cells were also 
cultured with an inhibitor to the aryl hydrocarbon receptor, which maintained the cells in an immature 
state. These cells were then studied at the functional and phenotypic level to detail the acquisition of 
known genetic changes in cells, and link them to clinical outcomes. 
Specifically, the researchers separated immature and more mature bone marrow cells by staining for 
cell surface markers and then using fluorescence-activated cell sorting. Less mature cells were  
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defined as those that expressed CD34 but lacked expression of CD33, whereas slightly more mature 
progenitors were defined as those that expressed both CD34 and CD33. Sorted cells were 
examined for the ability to give rise to myeloid colonies in vitro either immediately, 2, 4, 6, or 8 weeks 
after sorting. The resulting colonies were then subject to molecular analysis, assessing the clonality 
of the cells by examining X-inactivation of the HUMARA gene. As was seen in the classic Fialkow 
experiment, Walter observed that some patients exhibited polyclonality from long-term 
CD34+/CD33- culture indicating that the immature cells were predominantly normal, while other 
patients had clonality, indicating the leukemia originated in more immature cells. By performing 
these experiments on 50 AML patient samples with known clinical outcomes, the researchers found 
that patients with predominantly leukemic cells deriving from the most immature CD34+/CD33- 
population had significantly lower overall and relapse-free survival than those with predominantly 
normal growth (P=0.045 and P=0.03 respectively, see figure). 
In one subset of AML patient specimens, the researchers were able to use their methods to study 
the sequence of mutational acquisition for the first time in human specimens. These patients had a 
CBF translocation and other acquired mutations important for leukemogenesis. The researchers 
detected only CBF translocations in the most immature cells after long-term culture, and not the 
other acquired mutations. This result suggests that the CBF translocation arose first, priming cells to 
a pre-leukemic state, followed by additional mutations in more committed progenitor cells to develop 
full-blown AML.  
According to Dr. Walter, "combining functional assays with clinical information together suggests that 
not only is there heterogeneity with respect to the cell type in which AML mutations are acquired, but 
that the maturity of mutation acquiring cells may dictate patient outcome." Furthermore, Dr. Walter 
states that the data supports "the idea that the context in which the mutation occurs may be more 
important than the mutation per se." Dr. Walter cautions that newer targeted therapies aimed at 
eradicating AML stem cells cannot be a "one size fits all" approach, but may need to be tailored to 
the type of AML. Specifically, their results suggest that treatments which target cells with the more 
differentiated marker CD33 may fail for patients that acquire mutations in more immature stem cells.  
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If DNA mutations occur in more immature stem/progenitor cells in acute myeloid leukemia (AML) 
patients, overall and relapse-free survival rates are decreased. AML patients with more mature cells 
of mutation origin have a better prognosis. 
 
 
